RFK Jr. Amends ACIP’s Charter In Attempt To Exert More Control Over Panel Members

Why It Matters

The move tests the limits of executive power under the APA and could reshape how vaccine policy is crafted, affecting public‑health credibility and regulatory oversight.

Key Takeaways

• RFK Jr. rewrites ACIP charter to allow direct appointments
• New charter replaces expertise criteria with geographic and specialty balance
• ICAN and lawyer Aaron Siri drafted the charter amendments
• Court injunction remains, charter change unlikely to satisfy APA limits

Pulse Analysis

The Administrative Procedure Act (APA) serves as a guardrail against agency actions that lack evidentiary support or exceed statutory authority. In March 2026, a U.S. district court applied the APA to halt RFK Jr.’s ACAC‑driven vaccine schedule revisions, citing that the recommendations were not grounded in scientific data. The injunction underscored the judiciary’s willingness to enforce procedural rigor when public‑health panels stray from evidence‑based decision‑making.

Undeterred, Kennedy’s team issued a revised ACIP charter that subtly but significantly alters the appointment process. By changing the language to "selected and appointed by the HHS Secretary," the charter grants him unilateral power to install members, bypassing the traditional selection safeguards. Moreover, the new charter abandons the prior requirement that members possess specific immunization expertise, replacing it with a vague "geographic balance" and a wide‑ranging list of specialties. Drafted with input from the anti‑vaccine organization Informed Consent Action Network (ICAN) and attorney Aaron Siri, the amendments aim to broaden the panel’s composition to include advocates for vaccine‑injured individuals, diluting the scientific focus of the committee.

If the courts uphold the injunction, the charter revision may prove moot, but its existence signals a strategic attempt to reshape vaccine policy governance. A panel populated by non‑specialists could erode confidence in CDC recommendations, complicate federal‑state coordination during outbreaks, and invite further legal challenges. Stakeholders—from pharmaceutical firms to health insurers—must monitor how this power struggle evolves, as any weakening of evidence‑based vaccine guidance could have ripple effects across the broader public‑health ecosystem.